The present disclosure relates to a method for determining an ophthalmic lens adapted to slow down the progression of a vision impairment. The present disclosure also relates to a corresponding ophthalmic lens.
Vision impairment is in some cases defined by the fact that the eye does not focus objects on the retina. For example, in the case of myopia, the eye focuses distant objects in front of its retina. Myopia is usually corrected using a concave lens. Hyperopia is usually corrected using a convex lens.
For simplification, by way of non-limiting example, in the following, only the example of myopia will be considered. However, the present disclosure applies to other kinds of vision impairment as well.
Rather than merely correcting myopia, it is currently possible to slow down myopia, by providing ophthalmic lenses comprising predefined microstructures such as microlenses.
For instance, document WO-A-2019/166657 discloses a lens having such microlenses that compensate for some oblique astigmatism, so that for a 30° off axis angle, microlenses provide point focusing.
However, no means is provided for modifying or adjusting the lens characteristics based on the wearer's needs or individual parameters such as the prescription, fitting parameters, myopia control strength, etc.
Therefore, there is a need for improving myopia control for each individual wearer.
An object of the disclosure is to overcome the above-mentioned drawbacks of the prior art.
To that end, the disclosure provides a method for determining an ophthalmic lens adapted to slow down the progression of a vision impairment of an eye of a wearer according to claim 1.
Thus, the proposed method takes into account the prescription of the considered wearer as well as the need for slowing down the progression of the wearer's vision impairment for determining an optimized front and/or back surface of an ophthalmic lens that will improve the slowing down of the progression of that vision impairment, starting from an available collection of semi-finished lenses.
To the same end as mentioned above, the present disclosure further provides a computer program product according to claim 11.
To the same end as mentioned above, the present disclosure further provides a non-transitory information storage medium according to claim 12.
As the advantages of the computer program product and of the computer-readable storage medium are similar to those of the method, they are not repeated here.
The computer program product and the computer-readable storage medium are advantageously configured for executing the method in any of its execution modes.
For a more complete understanding of the description provided herein and the advantages thereof, reference is now made to the brief descriptions below, taken in connection with the accompanying drawings and detailed description, wherein like reference numerals represent like parts.
In the description which follows, although making and using various embodiments are discussed in detail below, it should be appreciated that as described herein are provided many inventive concepts that may embodied in a wide variety of contexts. Embodiments discussed herein are merely representative and do not limit the scope of the disclosure. It will also be obvious to one skilled in the art that all the technical features that are defined relative to a process can be transposed, individually or in combination, to a device and conversely, all the technical features relative to a device can be transposed, individually or in combination, to a process and the technical features of the different embodiments may be exchanged or combined with the features of other embodiments.
The terms “comprise” (and any grammatical variation thereof, such as “comprises” and “comprising”), “have” (and any grammatical variation thereof, such as “has” and “having”), “contain” (and any grammatical variation thereof, such as “contains” and “containing”), and “include” (and any grammatical variation thereof such as “includes” and “including”) are open-ended linking verbs. They are used to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps or components or groups thereof. As a result, a method, or a step in a method, that “comprises”, “has”, “contains”, or “includes” one or more steps or elements possesses those one or more steps or elements, but is not limited to possessing only those one or more steps or elements.
The flow diagram of
By way of non-limiting example, the vision impairment may be myopia. However, as indicated above, the present disclosure applies to other kinds of vision impairment as well.
The ophthalmic lens has a front surface and a back surface. Furthermore, on the front surface, or on the back surface, or on both the front and back surfaces, or between the front and back surfaces, the ophthalmic lens has one or more optical areas not focusing an image on the retina of the eye.
By way of non-limiting example, the optical areas may comprise one or more micro-structures, such as microlenses. The optical areas may have various shapes, such as rings, or circles, or hexagonal shapes, or elliptical shapes, or free form surfaces, or NURBS (Non-Uniform Rational B-spline Surfaces). This list of examples is not limiting.
As shown in
As additional wearer parameters, if the considered vision impairment is myopia, the myopia progression rate may also be provided.
Fitting parameters may also be provided as additional wearer parameters.
Based on at least the prescription and optionally based on additional wearer parameters, during a next step 12, a semi-finished lens that best corresponds to at least the prescription and that optionally also best corresponds to the additional wearer parameters is selected among a plurality of semi-finished lenses.
If the considered vision impairment is myopia, in a first non-limiting example where there are optical areas only on the front surface of the semi-finished lens, the specification of the optical areas is dependent on the sphere prescription. For higher myopia, there will be more optical areas on the front surface and the optical areas will have more power/asphericity. Table 1 below gives corresponding examples of values of the sphere (in diopters), the front base curve (in diopters), the density of optical areas (in %), the mean power addition of the optical area (in diopters) and the power variation of the optical area (in diopters), which measures the asphericity of an optical area.
In this first example, since most of the characteristics of the optical areas are built on the front surface of the semi-finished lens, the calculated back surface should not deviate a lot from an aspheric/atoric surface, in order to minimize the wearer power and resulting astigmatism.
If the considered vision impairment is myopia, in a second non-limiting example where there are optical areas only on the front surface of the semi-finished lens, example values of minimal characteristics of the optical areas that are constant with respect to the sphere prescription are given in Table 2 below.
In this second example, a significant modification work may have to be carried out on the semi-finished lens in order to obtain a satisfying final ophthalmic lens. This may be advantageous when using a prediction of myopia evolution for a specific wearer. Indeed, a model could take as inputs a number of eye characteristics of the wearer (axial length, aberrations, peripheral refraction, etc.), as well as other possible factors (age, history of high myopia in the family, etc.) and return a predicted rate of myopia evolution. Low, respectively high, predicted myopia rates will require lower, respectively higher, densities of optical areas i.e. myopia control areas and these areas will be of lower, respectively higher, power/asphericity.
If the considered vision impairment is myopia, in a third non-limiting example where there are optical areas only on the front surface of the semi-finished lens, another possible set of semi-finished lenses is a set of different base curves combined with different strengths (power or density) of optical areas based on a predicted rate of myopia evolution for the wearer, so as to take account of the fact that for similar prescriptions, different wearers may have different predicted rates of myopia evolution. Table 3 below gives examples of values of the sphere (in diopters), the front base curve (in diopters), the strength of the optical area, the density of optical areas (in %), the mean power addition of the optical area (in diopters) and the power variation of the optical area (in diopters).
If the considered vision impairment is myopia, in a fourth non-limiting example, there are no optical areas on the front surface of the semi-finished lens, but there are optical areas only on the back surface of the semi-finished lens. For instance, there may be only a varying continuous base curve for different prescriptions.
Thus, at the end of step 12, the semi-finished lens has been selected, so that the starting geometry of the lens is known and an optimization process will now be carried out, as described below.
The base geometry of the surface of the semi-finished lens comprising the optical areas, i.e. its front and/or back surface, may be a smooth portion outside the optical areas. It may be either aspheric, or even freeform (e.g. Zernike surface), so as to improve optical performance away from the central gaze direction. By way of non-limiting example, the free parameters for the optical areas may be the power, the area size and the density of optical areas.
As a variant, the base geometry of the surface of the semi-finished lens comprising the optical areas may be entirely freeform. Thus, there may be no predefined patterns of optical areas. In such an embodiment, the optical areas will appear at the optimization stage.
Returning to
Then, during a step 16, a cost function relating to the optical target(s) is minimized, so as to determine an optimized front and/or back surface of the semi-finished lens as the front and/or back surface of the final ophthalmic lens.
In a first embodiment, the optical targets comprise at least one target relating to a prescription area on the front surface and/or the back surface that corresponds to the wearer's prescription and at least one target relating to the one or more optical areas.
In that first embodiment, the optical targets are wearer power and resulting astigmatism targets for all gaze directions. Optical areas will purposely have power error and/or astigmatism.
Let us assume that the considered vision impairment is myopia and let us define GRX and GMC the sets of gaze directions, respectively for the prescription area and for myopia control i.e. the optical areas.
The complete cost functions may be decomposed into two parts.
For the prescription area part, the part CFRX(X) of the cost function, where X is the set of the degrees of freedom of the surface of the semi-finished lens being optimized, may be defined as follows:
where grx is a gaze direction, wrx is a positive weighting coefficient lower than or equal to 1, WearerPower is the lens power, T refers to the optical target and ResultingAstigmatism is the lens resulting (or unwanted) astigmatism, in which the cylinder and axis of the prescription are integrated.
Thus, the part CFRX(X) of the cost function is calculated for a first set of gaze directions GRX.
The prescription area will generally target a power error and an astigmatism equal to zero. This means that usually, WearerPowerTgrx is the mean spherical power of the prescription.
For the myopia control part i.e. the optical area part, the part CFMC(X) of the cost function may be defined as follows:
where gmc is a gaze direction, wmc is a positive weighting coefficient lower than or equal to 1 such that wrx+wrc=1, PowerError is the power error, T refers to the optical target, Astigmatism is the astigmatism and AstigmatismAxis is the axis of the astigmatism.
Thus, the part CFMC(X) of the cost function is calculated for a second set of gaze directions GMC.
WearerPowerTgrx will purposely be different from the prescription in order to create a defocus or unfocused signal with respect to the retina.
It is to be noted that the power/astigmatism calculation is performed in wearer mode, meaning that the incidence angle of the rays as well as the wearing parameters (eye-lens distance, pantoscopic/galb angles) are accounted for. Optical propagation software such as ray tracing or a refinement method using diffractive calculation may be used to calculate the optical propagation through the lens front surface, the lens substrate, the lens back surface, until reaching the defined gaze direction.
The optimization process then consists in minimizing a cost function that is the sum of the first cost function CFRX(X) including the first weighting coefficient wrx and the second cost function CFMC(X) including the second weighting coefficient wmc:
As a variant, the same method may be used for gaze directions relating to the prescription area and a different definition may be used for the optical area. For the optical area, PowerErrorg
The graph of
The graph of
The graph of
The graph of
As shown in
If the ophthalmic lens undergoes a coating process that is known to modify the properties of surfaces with optical areas, then the optimization and digital surfacing steps 16, 18 may be leveraged to compensate for such effect. Namely, if the coating process is known to modify an optical surface through a transfer function, then the optimization step will become minXCF(f(X)).
In a second embodiment, the optical targets relate to a modulation transfer function MTF, which may be an advantageous alternative to power error and resulting astigmatism. The MTF gives the modulation rate, i.e. the oscillation between white and black, representing the contrast between the image and the object, as a function of the measured spatial frequency of the discriminated objects.
In that second embodiment, the cost function is calculated for a set D of values of the diameter of the pupil of the eye and for a third set G of gaze directions. The third set of gaze directions is defined so as to reasonable constrain the optimization and ensure that the obtained front and/or back surfaces yield an ophthalmic lens the overall design of which is very close to the target.
By way of non-limiting example, D=[4 mm, 6 mm] and G is a uniform sampling of a 60° cone centered on the eye rotation center. Since a single calculation will use an extended area of the lens, there is no need to choose a very fine gaze sampling. A sampling step around 5° is sufficient. In addition, a single MTF calculation will capture both the prescription areas and the optical areas of the lens.
In that second embodiment, the cost function CF(X) may be defined as follows:
where d is a pupil diameter, g is a gaze direction, wg is a positive weighting coefficient lower than or equal to 1, T refers to the optical target and [fmin, fmax] is a spatial frequency range that is relevant to both visual acuity and myopia control. By way of non-limiting example, fmin=0 cycle per degree and fmax=30 cycles per degree.
For a specific gaze direction through the lens 30, a ray is propagated to the object space from the eye rotation center (ERC on the drawing). An object point is then calculated using an ergorama, which associates gaze directions to proximities. Let us denote ProxObj the object proximity of interest.
Assuming that the target wearer power is P, the image plane should be positioned at a proximity ProxIm=P−ProxObj from the vertex sphere, calculated along the ERC-pupil axis. The vertex sphere is centered on the ERC and intersects the back surface of the lens 30. The radius of the vertex sphere is the distance between the ERC and the lens 30.
Once the object point as well as the image plane are well defined, the point spread function (PSF) and the MTF are computed as they are usually computed for any optical system. Namely, a beam of rays is propagated from the object point to the eye entrance pupil (which is the same as he lens exit pupil), so as to perform a regular sampling of the pupil. The optical path lengths may be stored during this process. The optical path lengths are then used to compute the pupil function. A diffraction integral is then applied to the pupil function in order to obtain the PSF. Last, the MTF is computed from the PSF using a Fourier transform.
The above calculation is in “wearer mode”, meaning that the eye-lens distance as well as the pantoscopic and wrap angles and the fitting cross position are accounted for.
A variant of the method for determining an ophthalmic lens adapted to slow down the progression of a vision impairment of an eye of a specific wearer making it possible to reduce the calculation time by building a database of precomputed front and/or back surfaces is described below with reference to
During a first step 40, for each one of a plurality of prescriptions, the front and/or the back surface of the ophthalmic lens is precomputed, by applying the above-described method, namely, by:
Thus, a plurality of precomputed front and/or back surfaces is obtained.
The plurality of prescriptions may be defined by a sampling of the prescription space, as follows:
(S,C,A)i∈[Smin:Smax:ΔS]×[Cmin:Cmax:ΔC]×[Amin:Amax:ΔA]
where S is the mean sphere, C is the cylinder and A is the axis, min indicates the minimum value, max indicates the maximum value and Δ indicates the step between two successive values of the interval between the minimum and the maximum values.
By way of non-limiting example, if the considered vision impairment is myopia, the following values may be chosen:
This would yield 13×5×6=390 combinations, i.e. 390 prescriptions in the plurality of prescriptions.
During a following step 42, a plurality of parameters of the specific wearer is provided. It comprises at least a wearer prescription of the specific wearer and an indication about the need for slowing down the progression of a vision impairment of the eye of the specific wearer.
During a following step 44, a precomputed front and/or back surface is selected among the plurality of precomputed front and/or back surfaces, the corresponding prescription of the plurality of prescriptions being the closest to the wearer prescription of the specific wearer. As a variant, the precomputed front and/or back surface of the ophthalmic lens for the specific wearer may be interpolated from the surfaces of multiple nearby prescriptions.
Then, there are two options. Either, at a step 46, the front and/or back surface of the ophthalmic lens for the specific wearer is determined as the selected precomputed front and/or back surface obtained at step 44, or, at a step 48, the selected precomputed front and/or back surface obtained at step 44 is further optimized, by:
An ophthalmic lens according to the present disclosure is adapted to slow down the progression of a vision impairment of an eye of a wearer. It has a front surface and a back surface and at least one optical area on the front surface and/or on the back surface not focusing an image on the retina of the eye. The front surface and/or the back surface of the lens are determined by any of the above-described methods.
In a particular embodiment, the method according to the disclosure is computer-implemented. Namely, a computer program product comprises one or more sequences of instructions that are accessible to a processor and that, when executed by the processor, cause the processor to carry out steps of the method as described above for determining an ophthalmic lens adapted to slow down the progression of a vision impairment of an eye of a wearer.
The sequence(s) of instructions may be stored in one or several non-transitory computer-readable storage medium/media, including a predetermined location in a cloud.
The present disclosure makes it possible not only to significantly improve the slowing down of the progression of a vision impairment with respect to prior art methods, but also to best preserve visual acuity for all gaze directions, including when looking through the parts of the ophthalmic lens comprising the above-mentioned optical areas not focusing an image on the retina.
Although representative systems and methods have been described in detail herein, those skilled in the art will recognize that various substitutions and modifications may be made without departing from the scope of what is described and defined by the appended claims.
Number | Date | Country | Kind |
---|---|---|---|
21306610.3 | Nov 2021 | EP | regional |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2022/073997 | 8/30/2022 | WO |